

# Strategic performance report

Strategic delivery:	⊠ Setting standards	☑ Increasing and informing choice	☑ Demonstrating efficiency economy and value
Details:			
Meeting	Authority		
Agenda item	6		
Paper number	HFEA (09/03/2016) 786	3	
Meeting date	9 March 2016		
Author	Paula Robinson, Head	of Business Planning	
Output:			
For information or decision?	For information		
Recommendation	The Authority is asked to performance report.	to note and comment o	n the latest strategic
Resource implications	In budget		
Implementation date	Ongoing – strategic per	riod 2014-2017	
Communication(s)	CMG reviews performa comments are incorpora		Authority meeting, and their paper.
	The Department of Heameeting (based on the	-	ance at each DH Update
		n Directors. Authority's	each meeting, enhanced by views are fed back to the
Organisational risk	□ Low	⊠ Medium	□ High
Annexes	Annex 1: Strategic perfe	ormance report	

## 1. Introduction

- 1.1. The attached paper summarises the main performance indicators, following discussion by the Corporate Management Group (CMG) at its 17 February performance meeting.
- **1.2.** The majority of the data relates to the position at the end of December 2015. Some of the financial data also includes the position at the end of January 2016.
- **1.3.** Overall performance is good, and we are making good progress towards our strategic aims.

## 2. Recommendation

**2.1.** The Authority is asked to note the latest strategic performance report.


## **Annex A - HFEA strategic performance scorecard**

## 1. Summary section

## Dashboard - December data


#### Strategic delivery totaliser

(see overleaf for more detail)




#### **Setting standards:**

critical and major recommendations on inspection



## **Increasing and informing choice:**

public enquiries received (email)




## **Overall performance - all indicators:**

27 Red
- Amber
- Green
- Weutral

(See RAG status section for detail.)

## Efficiency, economy and value: Budget status: cumulative surplus/(deficit)


This graph details our net actual position as at end quarter 3 (month 9 – December 2015) and our forecast position at that time for 31 March 2016. The graph shows the expected deficit did not arise ie we are forecasting a surplus for the year. The components making up the surplus/deficit is shown later by two other graphs (income and expenditure).



## **Dashboard - Commentary**

## Strategic delivery (to end of December) – summary:





The totaliser data was significantly updated in December, to add all the IfQ work planned for delivery during beta phase. This work has started. There are a large number of key milestones that will be reached in the coming year. Owing to the major investment made to date in planning, arriving at various proofs of concept (in the alpha phase), and seeking various approvals, we are now in a position to build products (at the time of reporting this was at risk, since we were awaiting formal GDS approval; this was then received in January). This re-casting of the timeline data has made us appear 'behind' on the above graph. However now that real product development has commenced, we should expect to see the delivery line start to converge with the elapsed timeline over the coming months.

## Strategic delivery for September to December

#### **Setting standards**

In September, the compliance reports on risk tool alerts and themes, common non-compliances and incidents were all delivered on time to the Authority meeting, focusing on analysing current quality and safety issues in clinics, helping clinics to improve outcomes and reduce risks, and disseminating learning. Our annual publication reporting on clinical incidents (in 2014) was also published, containing information about learning points from incidents and adverse events, to inform both the clinics themselves and our future inspections. A multiple births stakeholder group meeting was also held as planned. We had originally planned to commission an external review of our inspection regime, to report in September, but a decision was taken to defer this work, pending the outcomes of our Triennial Review (which may include relevant recommendations).

In October, we completed the mitochondrial donation project, getting new application and licensing processes in place in time for implementation of the new legislation on 29 October. In addition we collaborated and engaged with others, through our own Licensed Centres Panel meeting and attendance of the AFPO conference held by patient and donor organisations.

#### Increasing and informing choice

Our six-monthly Choose a Fertility Clinic (CaFC) data was published on time in October, providing updated information (up to the end of quarter two of 2015 for pregnancy data) to the public and feedback on performance to the sector.

The annual report on clinical incidents and alerts was also published on time, in November.

#### Efficiency, economy and value

In September, work continued on the IfQ website and clinic portal projects. The alpha phase of work (proofs of concept) was subsequently completed in November, with approval to proceed obtained in principle following a very positive DH assessment. GDS approval was expected in December, but in the event was not received until January 2016. Meanwhile we took the decision to proceed with the beta phase at risk, since otherwise we would have needed to stand down our suppliers. Detailed beta phase planning has been completed, setting out the products and user stories that will be built and tested in each sprint. The Authority continues to receive regular reports on IfQ progress.

In October, our regular fees engagement with clinics took place. This meeting provides accountability and transparency on fee rates to the sector.

## Red/amber/green status of performance indicators as at December 2015

The red key performance indicators (KPI) shown in the 'overall status - performance indicators' pie chart on the dashboard are as follows:

The number of working days from the day of inspection to the day the draft report is sent to the PR has a target of 90% in 20 working days. In December performance was at 50%, with two out of four reports being sent at 27 working days. In one case this was because of unexpected additional workload, and in the other case the report took longer to refine since it was a template for future transport centre reports. There was also one report outstanding from November, which was sent 39 days after inspection. This was due to practical issues in obtaining a suitable peer review.

The total number of outstanding errors in the system taking into account the eight weeks centres are given to resolve rose by 16% in December, to 2,240. We attribute this to two main factors. Less proactive chasing is being undertaken since the team are prioritising correcting egg thaw treatment data to ensure correct linkage to freezing events and other important IfQ related work (an investment in improving accuracy in the future). There are also a number of new clinics with high error rates.


Two projects were on a red risk rating in December.

The Fertility Trends report project requires data for analysis, some of which (on egg freezing) requires cleansing before it can be used. This cleansing needs to be performed by the same staff who are currently cleansing the data for the IfQ-related data migration, and has had to be prioritised over that work. In addition, the report needs to be published at our Annual Conference on 24 March 2016, so the timeline is tight. Since December, the data cleansing required has progressed well, and the risk rating has been reduced to amber.

The Office Move project was also on a red risk rating in December, pending the resolution of some technical issues regarding our new internet connection (critical for business continuity). This has since been resolved, and the risk rating has accordingly been reduced to amber.


## **Budget status - January data**

The dashboard shows the overall surplus/deficit position. The graphs below show how the surplus or deficit has arisen. These figures are updated at least quarterly, approximately one month after the end of each quarter.



This graph shows our budgeted (planned) licence fee income and grant-in-aid (GIA) compared to what is actually happening.

As of month 10 (31 Jan-16) we are not far off our budget (a shortfall of only £44k). Treatment fees are the most variable of our income stream and will therefore continue to be monitored.



This graph is the second component that makes up the surplus/deficit. This excludes costs relating to IfQ, since this is being funded from reserves and accounted for separately.

Year to date we are under spending against budget (£317k) which is relative to our reduced income. The underspend has been added to by inclusion of receipts from legal cases where we were awarded costs. Our year end forecast is showing an under spend of £286k up from £177k reported at the end of Q3. This position may change as more information is known and on-going pieces of work are completed.


## **Quality and safety of care**

The following figures and graphs were run on 28 January 2016.

## **ESET split by private/NHS:**

Funding	Year									
	2010	2011	2012	2013	2014	2015	2016*			
NHS Funded:										
Recorded as	4294	4903	6264	7867	8443	9689	447			
eSET	7%	8%	10%	13%	13%	15%	19%			
Not recorded as	19283	19491	17869	17723	17837	16843	561			
eSET	33%	32%	30%	29%	28%	26%	24%			
Private:										
Recorded as	3422	4629	5698	6857	7732	9256	402			
eSET	6%	8%	9%	11%	12%	14%	17%			
Not recorded as	31019	31546	30400	29388	29558	29289	964			
eSET	53%	52%	50%	48%	46%	45%	41%			

## **Graph: eSet % trends NHS/private:**




Explanatory text: Looking at all IVF treatment forms; counting those records that the clinics recorded as eSET.

<sup>\*</sup> Very early 2016 data is provided for interest only, since it is too early in the year to draw any conclusions from it. This data is not included in the graph.

Unfiltered success rates as % - pregnancies (rather than outcomes, since this provides a better real-time picture):

#### Graph showing the pregnancy rate over recent years:

Years	All cycles	Pregnancies	Pregnancy rate %
2010	58018	16116	27.78
2011	60569	16896	27.89
2012	60231	17452	28.98
2013	61835	18648	30.16
2014	63570	19876	31.27
2015	65077	19776	30.39
2016	2374	1	0.04




**Explanatory text:** Looking at all IVF treatment forms, and providing a count of pregnancies - as recorded on the early outcome form.

As agreed previously, the following items are most meaningful when reported on an annual basis. The following items will continue to be presented to the Authority each year in September:

- number of risk tool alerts (and themes)
- common non-compliances (by type)
- incidents report (and themes).

## 2. Indicator section

## **Key performance and volume indicators – December data:**




wider families.

Percentage of
Opening the
Register requests
responded to
within 20 working
days



100%

(17)



Maintain at 100%



KPI: 100% of complete OTR requests to be responded to within 20 working days (excluding counselling time)

The dip in August reflects the summer holiday period.

<sup>&</sup>lt;sup>1</sup> Blue dashed line in graphs = KPI target level. This line may be invisible when performance and target are identical (eg, 100%).

<sup>&</sup>lt;sup>2</sup> Direction in which we are trying to drive performance. (Are we aiming to exceed, equal, or stay beneath this particular KPI target?)

Indicator

Performance RAG

97.490

Recent trend

Aim<sup>2</sup>

**Notes** 

Increasing and informing choice: using the data in the Register of Treatments to improve outcomes and research.

See graphs focused on quality of outcomes – after dashboard page.


#### Increasing and informing choice: ensuring that patients have access to high quality meaningful information.

Number of visits to the HFEA website (cw previous year)

website (cw previous year) (108,872) (trend arrow

indicates movement since previous month)






No KPI – tracked for general monitoring purposes. Volume indicator showing general website traffic compared to the same period in previous year. Measured on the basis of 'unique visitors'.

**Note:** This indicator was discussed at performance CMG in February. We noted that a dip is typical for December, but that there is still a downward trend, over all. The web team has done some analysis, which shows that our web pages are still well used and viewed. Our twitter following is rising, and there may be a correlation between the two trends. An annual review of our Communications Strategy will be presented to the Authority later this year, and will address this area.

#### Efficiency, economy and value: ensuring the HFEA remains demonstrably good value for the public, the sector and Government.


Average number of working days taken for the whole licensing process, from the day of inspection to the decision being communicated to the centre.


57 working days



Maintain at 70wd or less

KPI: Less than or equal to 70 working days.






**Note:** Last year's numbers were notably high. Many of those PQs related to the work we were then doing on mitochondria. However, figures are increasing markedly again in 2016 (January's figure is 18). However these are about a range of subjects, and none have been about mitochondria.

Number of
Freedom of
Information (FOI),
Environmental
Information
Regulations (EIR)
requests and Data
Protection Act
(DPA) requests




10



No KPI – tracked for general monitoring purposes.

Volume indicator.
There does not appear to be any trend or predictability in the volume or focus of our FOI (and other) requests.



Note: January's balance is approximately 15% below December's levels - £2,185k - helped by payment of December bills.

Recent trend<sup>1</sup>

Aim<sup>2</sup>

Notes

Management January 2016 accounts:

accounts: Income & Expenditue

Performance RAG

	Year to Date	ı		Full Year	
Actual YTD	Budget YTD	Variance YTD	Forecast	Budget	Variance £
£	£	£	£	£	£
840	840	_	1.120	1.120	_
·	5			6	50
4,314	4,358		5,201	5,246	
3,006	3,167	- 161	3,611	3,807	- 196
192			228		
115			154		
					23
66	55 55	- 92 11	78	68	- 44 10
4,070	4,441	- 371	5,028	5,314	- 287
244	- 83	327	174	- 69	243
537	864	- 327	945	1 135	- 190
8			8		
74	-	74	100	100	-
610	870	- 261	1 052	1 255	- 202
	Actual YTD £ 840 3,419 55 4,314 3,006 192 115 46 66 277 82 220 66 4,070 244	Actual YTD £  840 840 3,419 3,513 55 5  4,314 4,358  3,006 3,167 192 218 115 143 46 33 66 129 277 296 82 88 220 312 66 55  4,070 4,441  244 - 83  537 864 8 16 74 -	YTD £         YTD £         YTD £           840 840 3,513 - 94	Actual YTD £         Budget £         Variance YTD £         Forecast £           840         840         -         1,120           3,419         3,513         -         94         4,025           55         5         50         56           4,314         4,358         -         44         5,201           3,006         3,167         -         161         3,611           192         218         -         26         228           115         143         -         27         154           46         33         13         62           66         129         -         63         164           277         296         -         19         339           82         88         -         7         96           220         312         -         92         296           66         55         11         78           4,070         4,441         -         371         5,028           244         -         83         327         174           537         864         -         327         945           8	Actual YTD £         Budget £         Variance YTD £         Forecast £         Budget £           840         840         -         1,120         1,120           3,419         3,513         -         94         4,025         4,120           55         5         50         56         6           4,314         4,358         -         44         5,201         5,246           3,006         3,167         -         161         3,611         3,807           192         218         -         26         228         258           115         143         -         27         154         166           46         33         13         62         39           66         129         -         63         164         175           277         296         -         19         339         355           82         88         -         7         96         106           220         312         -         92         296         340           66         55         11         78         68           4,070         4,441         -         371         <

#### Income

Treatment fee income for the year to date is 3% down against budget and 2% below the same period in 2014-15.

We are forecasting a short fall of 2% compared to budget. The shortfall reflects the trend we have experienced over the last twelve months. We continue to keep a close eye on this.

Other income excluding interest on legal fees is 8% up on budget and we are expecting this to remain until year end.

#### **Expenditure**

Year to date non pay expenditure is 16% below budget at the end of January 2016.

There are underspends across directorates relating to publications, stakeholder relations, media and administration and legal costs (where we have been reimbursed some costs). These are offset by over spends on external inspection costs, and PGD application review fees which were not budgeted for.

Staff costs for the year to date are under budget by 5% and this has been affected by vacancies during the year.

A further review was conducted in early February. Before spend on IfQ, we are forecasting overall expenditure to be 8% lower than what we have budgeted. Subject to there being no surprises, it is likely that this will be maintained until year-end.

#### IfQ and other project costs

The pace of spend increased slightly in January (cumulative spend now at £537k compared to budget of £864k), with the year to date underspend increasing to 38%.

Our forecast at year end has been reviewed. We expect that £945k of our original total budget (£1,135k) will now be spent. There will be some carry-over to 2016/17 which may be in the region of £200k.

## IfQ indicators: December update for Beta project phase

Frequency / trigger point	Metric	Purpose	Latest status:
At programme set-up / major reorganisation / new tranche	MSP health check overall score achieved / maximum score as a %	Is the programme set up to deliver?	The annual health check has been postponed until February.  This piece of work has been delayed by IfQ handover work, including significant workload associated with updating the budget, contract sign-off for beta, sprint re-planning for beta, and daily project support activities.
Monthly	Timescales: burndown chart showing remaining estimate of work.	Is there scope creep/over- run?	In beta sprint two (in January) half of the assigned tasks were completed.  The remaining tasks were either not started or part-completed, with outstanding actions reallocated to beta sprint three.  We purposely over-allocated the first sprints of beta in order to give flexibility in the event of any blockage. Nonetheless, if the above trend were to continue this would have an impact on the timeline.  Scope creep is being contained, however, and the beta deliverables have been confined to the minimum viable products (MVPs) identified in the product backlogs.
Monthly	Resource usage: The total number of days Reading Room are contracted to provide, vs the number of days consumed to date.	To monitor the rate of resource usage.	The external resources utilisation figures for beta (sprints 1 and 2) were provided by RR on 1 February 2015. This showed an above pro-rata consumption of the resource days in the first two sprints of beta. However we anticipate that in the last four sprints of beta the requirement for RR resources will be decreasing due to the GDS/DH planned downtime. This will continue to be monitored.

Freq- uency / trigger point	Metric	Purpose	Latest s	tatus:											
Monthly	Cost: earned value (% complete * estimated spend at completion)	Is the spend in line with milestone delivery?	cost at control to the major part of the major part of the major part of the major part of the program of the p	defined ompletion of below ain contryment (for at that provides with specific the being gramme	I dataset on has be shows e actor, R for alpha boint. No end. The investe complete ry.	discovered view that we earned dinto de ed an im	ery, stake outed to alue ver Room), covork) ware are in value or tailed be portant	eholder each pro rsus sper occurs or as made beta, ar nly increate eta plann	engager oject. nd, to da nly at the in Dece nd buildir ased by ning and e when	nent etc ate. How e end of mber, wl ng produ two pero readjust	ever, in peach phanich caudets, we detent in Determinent of	practice, ase of wises the sexpect the curre eway as	our mai ork, ie, r spend fig ne earne r due to ent timel	in spend not montl gure to ju d value of the major	ogramme (payments nly. Our first
			0.0%	Jan-15	Feb-15	Mar-15	Apr-15	May-15	Jun-15	Jul-15	Aug-15	Sep-15	Oct-15	Nov-15	Dec-15

	Strategic performance report		Human Fertilisation and Embryology Authority 19						
Freq- uency / trigger point	Metric	Purpose	Latest status:						
Monthly	Stakeholder engagement: combined stakeholder engagement score (internal plus external stakeholder events)	Are we keeping stakeholders with us? Is it getting better or worse?	There are monthly 'show and tell' sessions in place for staff. There was also an information giving session lfQ at our all staff conference in December.  We are holding external lfQ stakeholder group meetings monthly. In addition we are including articles about the lfQ programme in Clinic Focus and stakeholder publications.  Total combined score (December) = 4.						
Monthly	Risks: sum of risk scores (L x I)	Is overall risk getting worse or better (could identify death by a thousand cuts)?	The below line graph represents the overall IfQ risk score, which combines the perceived impact and likelihoo of the current risks on hand each month. The overall risk score for the IfQ Programme has decreased as previous risks have been mitigated and closed. The largest proportions of our risk score are associated with resources, quality and development. More information is available in the risk log regarding severity and rating. In January, a thorough comb of the risk log was done, resulting in the closure of some risks – this can be seen in the graph below.						

Strategic p	egic performance report		Human Fertilisation and Embryology Authority 20
Freq- uency / trigger point	Metric	Purpose	Latest status:
Quart- erly	Benefits: value (£) of tangible benefits planned to be delivered by the programme	Is the value of the benefits increasing or decreasing – could trigger a review of the business case?	The benefits realisation value should be reviewed based on the business case; this will be looked at during the next IfQ Programme Board meeting. No issues have been raised regarding benefits realisation to date.